Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006 Sep; 176(3):972-8; discussion 978.

View in: PubMed

collapse authors with profiles